ATCC Collaboration Aimed at Pancreatic Cancer Biomarker Development
News Nov 02, 2007
ATCC (American Type Culture Collection) has announced a research collaboration with The Valley Hospital of Ridgewood, New Jersey that will help speed the development and validation of biomarkers for the early detection and treatment of pancreatic cancer.
The Valley Hospital will provide ATCC scientists with high-quality and highly annotated tissue from patients who agreed to allow their resected pancreatic tumors to be used in future studies. ATCC will conduct the biomarker discovery research. Valley will also provide stored blood and practical clinical perspectives on validation and application of the collaboration’s biomarker discoveries.
“ATCC’s collaboration with The Valley Hospital exemplifies ATCC’s commitment to translational research,” remarked Dr. Cohava Gelber, ATCC Chief Science and Technology Officer. “I’m confident that combining the capabilities of The Valley Hospital’s tissue acquisition and clinical experience with the systems biology approach of ATCC will make for a successful collaboration.”
The ATCC research team will subject the pancreatic cancer samples to a proprietary biomarker discovery platform. The platform consists of integrated proteomics, genomics, bioinformatics and immunology paradigm and has already demonstrated effectiveness in uncovering novel biomarkers for type 2 diabetes.
This collaboration will focus on finding biomolecules that enable early detection, therapeutic monitoring and potentially treatment of pancreatic cancer. ATCC scientists will also utilize the ATCC Cell Biology Collection to test for the presence or absence of various biomarkers across a wide range of cell lines. ATCC and The Valley Hospital will form a Joint Research and Development Committee of scientists and physicians to consult on the objectives and progress of the research initiatives.
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.